Thus, we have initiated the first clinical study treating patients with ovarian cancer with combinational therapy consisting of ACT, anti-PD1, anti-CTLA4, and anti-LAG3 (ClinicalTrials.gov identifier: NTC04611126). This evidence concerns the gene CTLA4 and ovarian carcinoma.